mc vc pab sn38

Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.

SN-38 (NK012) is the active metabolite of Irinotecan, a DNA topoisomerase I (Topo I) inhibitor, which inhibits DNA and RNA synthesis (IC50=0.077/1.3 μM). SN-38 has antitumor activity and induces autophagy.

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Val-Ala-PAB, an effective linker, is utilized in antibody-drug-conjugate (ADC).

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

MC-SN38 is a drug-linker conjugate that pairs the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for use in antibody drug conjugates (ADCs). SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan, works by inhibiting DNA synthesis and inducing DNA single-strand breaks.

PC5-VC-PAB-MMAE is a conjugate comprising the ADC linker (PC5-VC-PAB) and the potent tubulin inhibitor (MMAE), functioning as an agent-linker conjugate for antibody-drug conjugates (ADC) [1].

MC-VC-PAB-NH2 is a cleavable linker crucial in ADC (antibody-drug conjugate) synthesis. It facilitates the attachment of cytotoxic drugs to antibodies, allowing targeted delivery to specific cells or proteins. Its cleavable nature ensures controlled drug release, thereby optimizing the effectiveness of ADCs.

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

MC-VC-PAB-NH2 TFA is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Azide-PEG4-VC-PAB-Doxorubicin is an agent-linker conjugate used in antibody-drug conjugate (ADC) applications, comprising the cytotoxic anthracycline antibiotic Doxorubicin linked through the Azide-PEG4-VC-PAB linker [1].

Mc-Val-Cit-PAB-Gefitinib chloride is a conjugate agent-linker for antibody-drug conjugates (ADCs) that combines Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the proprietary ADC linker Mc-Val-Cit-PAB [1].

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate for Antibody-Drug Conjugates (ADCs), incorporating Aur0101, an auristatin microtubule inhibitor, linked via the MC-VC-PABC linker to boost antitumor efficacy.

Mc-Gly-Gly-Phe-Gly-PAB-OH, also known as Mc-GGFG-PAB-OH, is a cleavable ADC linker used specifically in the synthesis of antibody-drug conjugates (ADCs).

MC-VC-PABC-C6-alpha-Amanitin is an antibody-drug conjugate that combines the anticancer toxin alpha-Amanitin with the monoclonal antibody MC-VC-PABC-C6. Alpha-Amanitin, a potent inhibitor of RNA polymerase IIα, enables the conjugate to selectively target and recognize HER2-positive tumor cells, making it a valuable research tool in the study of breast and gastric cancers [1].

MC-VC-PAB-MMAD is a conjugate for antibody-drug conjugates (ADCs) that exhibits potent antitumor activity by employing MMAD, a powerful tubulin inhibitor, connected through the cleavable ADC linker MC-VC-PAB [1].

MC-VA-PAB-Exatecan is an agent-linker conjugate designed for Antibody-Drug Conjugate (ADC) applications, comprising the ADC linker (peptide MC-VA-PAB) and the DNA topoisomerase I inhibitor Exatecan. Synthesis of this conjugate has demonstrated promising antitumor activity [1].

SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-cancer agent SN38 linked to Lys(MMT)-PAB-oxydiacetamide-PEG8-N3. It serves as a click chemistry reagent featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-bearing molecules and can also engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with compounds containing DBCO or BCN groups, facilitating the synthesis of ADCs [1].

Mal-VC-PAB-ABAEP-Azonafide, an ADC (antibody-drug conjugate) linker-drug conjugate, demonstrates potent antitumor activity. It incorporates Azonafide, a cytotoxin, connected through the ADC linker Mal-VC-PAB[1].

Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC Cytotoxin: Exatecan) [1].

MC-VAL-CIT-PAB-VX765 or MC-VAL-CIT-PABC-VX765 is a VX765 derivative that can be conjugated to antibodies, proteins, or polymers for targeted drug delivery. MC-Val- CIT -PAB is a cathepsin cleavable ADC connector, which has been widely used in the preparat

CL2-SN-38, a part of the antibody-drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is an inhibitor of DNA topoisomerase I.

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker, which endows it with significant antitumor activity.

MC-vc-PAB-Tubulysin M is a conjugate comprising a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis.

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) that employs a protein-degrading agent (protac molecular glue, etc.).

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), incorporating Dolastatin10 (a tubulin polymerization inhibitor) connected via the MC-Sq-Cit-PAB ADC linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

TCO-PEG4-VC-PAB-MMAE is an agent-linker conjugate used in antibody-drug conjugates (ADCs), consisting of a cleavable linker (TCO-PEG4-VC-PA) and the potent tubulin inhibitor MMAE [1].

MC-VC-PAB-Cyclohexanediamine-Thailanstatin A, a spliceostatin analog and drug-linker conjugate for antibody-drug conjugates (ADC), comprises the cytotoxic component Thailanstatin A and the cleavable linker (MC-vc-PAB). This compound is utilized in the synthesis of ADCs [1].

GGGDTDTC-Mc-vc-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), containing monomethyl auristatin E (MMAE), a tubulin inhibitor, as the cytotoxic component [1].

Mal-VC-PAB-PNP-CDN-A is a conjugate used in antibody-drug conjugates (ADC), consisting of an agent and a linker [1] [2].

OSu-Glu-VC-PAB-MMAD is an agent-linker conjugate used in antibody-drug conjugates (ADCs) with potent antitumor activity. It features MMAD, a powerful tubulin inhibitor, linked via the cleavable ADC linker OSu-Glu-VC-PAB, enabling targeted cancer therapy.

Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine, an immune stimulator antibody conjugate (ISAC), comprises an anti-human epidermal growth factor receptor 2 (HER2) antibody, a STING agonist (ADU-S100), and a linker, and is used in cancer research.

Bi-Mc-VC-PAB-MMAE is an agent-linker conjugate for antibody-drug conjugates (ADCs), featuring the linker (Fmoc-Val-Cit-PAB) and the potent tubulin inhibitor (MMAE).

OSu-PEG4-VC-PAB-MMAE is utilized in the synthesis of GDP-FAmP 4 MMAE (Monomethylauristatin E), specifically for GDP labeling through site-specific conjugation [1].

MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent Eg5 inhibitor and a click chemistry reagent [1].

CL845-PAB-Ala-Val-C5-MC, a conjugatable STING ligand, derives from the proprietary cyclic dinucleotide CL845 and is designed for bioconjugation.

MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which encompasses metabolites of nemorubicin (MMDX) derived from liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to connect with the potent antitumor agent dimethylDNA31, which also demonstrates significant bactericidal activity against both persister and stationary-phase [Staphylococcus aureus].

Mal-PEG4-VC-PAB-DMEA, a cleavable ADC linker incorporating a Maleimide moiety, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

SN-38 glucuronide, an inactive metabolite of Irinotecan, serves as a derivative of this cancer-fighting agent. Irinotecan, known for inhibiting topoisomerase I, is utilized in the research of colon and rectal cancer [1].